BACKGROUND Clinical trial data provide an approach to the investigation of the effects of psychopharmacological agents, and psychiatric disorders themselves, on seizure threshold. METHODS We accessed public domain data from Food and Drug Administration (FDA) Phase II and III clinical trials as Summary Basis of Approval (SBA) reports that noted seizure incidence in trials of psychotropic drugs...

In light of the large number of studies published since the 2004 update of Schizophrenia Patient Outcomes Research Team psychopharmacological treatment recommendations, we conducted an extensive literature review to determine whether the current psychopharmacological treatment recommendations required revision and whether there was sufficient evidence to warrant new treatment recommendations fo...

Modern development trends in psychiatry incorporate greater care for patients and above all individualisation of therapeutic approaches. Therapeutic drug monitoring (TDM) for phenotyping and genotyping of drug metabolism are possible determinants of improved treatment efficacy, reduced adverse effects of psychotropic drugs, and enhanced treatment compliance. They render possible individual adju...

OBJECTIVE To review the historical development of the psychopharmacological treatment of schizophrenia. METHOD A chronological literature review of the clinical practices and theoretical models that have controlled drug treatment of schizophrenia at different times. RESULTS Effective treatment of schizophrenia was achieved only after the introduction of antipsychotic drugs, in the 1950s, an...

This practice parameter describes the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder (ADHD) based on the current scientific evidence and clinical consensus of experts in the field. This parameter discusses the clinical evaluation for ADHD, comorbid conditions associated with ADHD, research on the etiology of the disorder, and psychopharmacolo...

Some patients with severe mental disorders are refractory to psychotherapeutic or psychopharmacological interventions. We describe a patient with severe symptoms from the age of 16 to 44. Her illness is best described as a schizo-affective disorder. Several series of electroconvulsive therapy (ECT) followed by maintenance once a week for more than six years has kept her out of hospital beds for...

This practice parameter describes the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder (ADHD) based on the current scientific evidence and clinical consensus of experts in the field. This parameter discusses the clinical evaluation for ADHD, comorbid conditions associated with ADHD, research on the etiology of the disorder, and psychopharmacolo...